Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Three directors bought COO stock in the open market in the days after a brutal September earnings selloff, a cluster of discretionary purchases that stands out against a stock down nearly 19% over the past month.
The insider buying is the most concrete show of conviction in weeks. Director Lawrence Kurzius bought 20,000 shares across two transactions on September 14 and 16, spending just over $1.08 million at prices around $54. Walter Rosebrough added 10,000 shares across the same period for roughly $541,000. Paul Keel picked up a further 4,700 shares at $53.18. None of these trades were made under a pre-arranged 10b5-1 plan, meaning they were discretionary calls rather than scheduled sales-plan mechanics. The 90-day net across all open-market activity totals about 34,700 shares and just under $1.9 million in value. That is a meaningful cluster for a mid-cap health care name.
The catalyst for the selloff, and the buying opportunity directors appear to have seized, was the September 9 earnings print. The stock dropped nearly 20% on the day and held most of that loss over the following five days. CooperVision, the contact lens engine that drives the bull case, posted zero organic growth. Management cut full-year revenue guidance to a range of $4.229 to $4.252 billion and trimmed EPS expectations to $4.51 to $4.55. The bear case in brief: US channel inventory de-stocking of around $20 million hit CooperVision, Asia-Pacific remained soft, and a rising FY27 tax rate to 17.5% clouds the recovery trajectory. Against that, the company generated revenue of $1.082 billion on an adjusted basis, expanded operating margin to 26.3%, and lifted free cash flow guidance to $650 million for the year, facts the bulls point to as evidence the franchise is intact even if the near-term demand picture is messy.
The Street response to the print was swift and broadly negative. A wave of target cuts hit on September 10: JP Morgan's Robbie Marcus trimmed to $58 from $71 while staying Neutral. Piper Sandler cut to $59 from $86 and downgraded to Neutral. Citigroup went to $60 from $80. Mizuho kept Outperform but lowered to $75 from $85. William Blair downgraded outright to Market Perform. Needham reiterated Buy at $73 on September 15, a lone voice maintaining optimism. Then on October 7, Barclays initiated coverage with an Equal-Weight rating and a $60 target, essentially endorsing the "not yet" view. The consensus is Hold. The mean price target of $65.80 implies about 17% upside from the current $56.43 close, but with the stock at a 12x trailing PE and price-to-book near 1.3x, that target range has been moving lower rather than higher. EPS momentum over both 30 and 90 days ranks in the bottom quarter of the universe, though the company's track record of beating estimates ranks near the top.
Short positioning is a secondary story here, not the main event. Short interest has risen about 24% over the past month to roughly 4.8% of the free float, a genuine build but not an extreme level. Borrow remains cheap at around 0.52% annualised, down about 15% on the week. Availability is extremely loose at over 2,200%, meaning there is no structural squeeze pressure in the lending pool. Options positioning is slightly more call-skewed than usual, with the put/call ratio at 0.39 running just below its 20-day average of 0.41, a near-flat reading that reflects neither strong hedging demand nor aggressive bullish speculation. The borrow market and options market together suggest shorts are rebuilding positions after the earnings gap, but without urgency.
One alt-data item worth noting: Cooper's remaining share buyback authorisation stood at $860.8 million as of Q2 2026, up 299% year-on-year and the largest Q2 authorisation on record back to 2015. With the stock near multi-year lows and free cash flow guidance upgraded, management's use of that buyback capacity between now and the December 3 next earnings date is the clearest near-term signal to watch.
See the live data behind this article on ORTEX.
Open COO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
